Impact of Estimated Glomerular Filtration Rate and Serum C‐Reactive Protein Level to Overall Survival After Second‐Line Targeted Therapy Following Immuno‐Oncology Combination Therapy for Advanced Renal Cell Carcinoma

Documenti analoghi

• Comparative Efficacy of First‐Line Immune Checkpoint Inhibitor‐Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort Study
  di: Keita Tamura, et al.
  Pubblicazione: (2026)
• Editorial Comment on Bayesian Reinterpretation of the CheckMate ‐ 9ER Final Analysis: Organ‐Site and IMDC Risk‐Stratified Probabilities of Benefit
  di: Koji Iinuma, et al.
  Pubblicazione: (2026)
• Impact of Impaired Renal Function on the Efficacy and Safety of Second‐Line Tyrosine Kinase Inhibitor Therapy After First‐Line Immuno‐Oncology Combination Therapy in Metastatic Renal Cell Carcinoma: A Japanese Multicenter Retrospective Study
  di: Naoki Fujita, et al.
  Pubblicazione: (2025)
• Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study
  di: Koji Iinuma, et al.
  Pubblicazione: (2026)
• Robot‐Assisted Radical Cystectomy Using the Hinotori Surgical System in Patients With Previous Prostate Cancer Treatment: A Single‐Institution Case Series
  di: Kosuke Uchida, et al.
  Pubblicazione: (2026)